On December 2, Bradley Fluegel notified the Board of Directors of NeuroMetrix (NURO), of his decision to resign from the Board and as a member of the Board’s Audit Committee, effective as of December ...

Medical device maker NeuroMetrix has agreed to pay $3.7 million to settle federal allegations that it gave kickbacks to physicians, according to news releases from the U.S. Attorney’s Office and ...

WOBURN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial ...

WOBURN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (“NeuroMetrix” or the “Company”) (Nasdaq: NURO) today announced it has entered into a ...

WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation device as an ...

Shares have lost half their value since this spring as a number of insurers have said they would restrict reimbursement for the company's nerve tests. But some investors are betting doctors who find ...

WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO) today reported that Michael MacDonald has been promoted to SVP and General Manager of Diagnostics. In this role, Mr. MacDonald will ...

Neurometrix Inc. (NASDAQ:NURO) shares flew higher Tuesday and Wednesday on continued momentum after the company announced its Quell device received Breakthrough Designation from the FDA for treating ...

WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq:NURO), today announced that it has completed its private placement of common stock and warrants. Gross proceeds from the offering were ...